一线贝伐珠单抗治疗浆液性上皮性卵巢癌：FINAVAST 试验的生物标志物分析。

Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.

机构信息

Department of Oncology and Radiotherapy, P.O. Box 22, FIN-90029 Oulu University Hospital, Finland.

出版信息

Anticancer Res. 2010 Mar;30(3):1001-6.

PMID:20393027

Abstract

BACKGROUND

Potential tissue and serum biomarkers were assessed for predicting efficacy of bevacizumab in ovarian cancer (OC).

PATIENTS AND METHODS

Twenty patients with OC received chemotherapy alone (control group) or in combination with bevacizumab (study group) in this non-randomised study. Pre- and post-treatment serum concentrations of vascular endothelial growth factor (VEGF), 8-hydroxydeoxyguanosine (8-OHdG) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured in all patients. In addition, immunohistochemical expressions VEGF receptors (R1, R2), hypoxia-inducible factor 1alpha (HIF-1 alpha), matrix metalloproteinases (-2, -9) and TIMP-2 were analysed in tumours from bevacizumab-treated patients.

RESULTS

8-OHdG and HIF-1alpha immunostainings were more highly expressed among patients with progression-free survival (PFS) >23 months than in patients with PFS <12 months. Similarly, MMP-9 was more frequently highly expressed in those with long versus short PFS. Serum VEGF concentrations decreased substantially in all bevacizumab-treated patients versus only 20% of the control group.

CONCLUSION

Our results indicate differences in MMP-9 and HIF-1alpha expression in relation to duration of PFS and effects on serum VEGF when bevacizumab is used in combination with chemotherapy.

摘要

背景

评估了潜在的组织和血清生物标志物，以预测贝伐单抗在卵巢癌 (OC) 中的疗效。

患者和方法

在这项非随机研究中，20 名 OC 患者接受了单独化疗（对照组）或联合贝伐单抗治疗（研究组）。所有患者均检测了治疗前后血清血管内皮生长因子 (VEGF)、8-羟基脱氧鸟苷 (8-OHdG) 和金属蛋白酶组织抑制剂-1 (TIMP-1) 的浓度。此外，还分析了接受贝伐单抗治疗患者肿瘤中 VEGF 受体 (R1、R2)、缺氧诱导因子 1alpha (HIF-1alpha)、基质金属蛋白酶 (-2、-9) 和 TIMP-2 的免疫组化表达。